pharma · Colon Carcinoma Metastatic in the Liver · Metastatic Melanoma · VCNX
Vaccinex
VACCINEX, INC.
Vaccinex is a pharma organization headquartered in Rochester, USA. It trades on NYSE under ticker VCNX. Primary therapeutic focus areas include Colon Carcinoma Metastatic in the Liver, Metastatic Melanoma, Metastatic Pan
1895 Mt Hope Ave, Rochester, New York 14620, US HQ
28 Employees
Public company Type
VCNX · NYSE Ticker
Company details
- Status
- Public
- HQ
- 1895 Mt Hope Ave, Rochester, New York 14620, US
- Employees
- 28
- Programs
- 11
- Drugs
- 8
- Patents
- 41
pepinemab + pembrolizumab
Phase 2 · small molecule · Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
pepinemab + pembrolizumab for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) is a Phase 2 program (small_molecule) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).
Internal code VX15/2503-12
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- VACCINEX, INC.
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
- Status
- completed
- Trials
- 1